Barclays
CPHR

Barclays’s Cipher Pharmaceuticals Inc. CPHR Stock Holding History

Barclays’s Portfolio CPHR Stock Details CPHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-300
Closed -$1K – 7066
2015
Q3 		$1K Buy
+300
New +$2.08K ﹤0.01% 6743

Other funds holding CPHR

MBI
Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
TAM
Taylor Asset Management Toronto, Ontario, Canada $154M AUM 10.32% 1-Year Est. Return
NEI
Northwest & Ethical Investments Toronto, Ontario, Canada $4.32B AUM 23.26% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's CPHR Position: Q4 2015 in Review

Barclays sold out of Cipher Pharmaceuticals Inc. (CPHR) in Q4 2015, closing a stake of 300 shares — an estimated $1K sold.

Barclays first reported a position in CPHR in Q3 2015 and held it in 1 quarter. The position peaked at $1K in Q3 2015. 21 funds tracked by Wall St. Rank hold CPHR as of Q4 2015.

  • Barclays reported no remaining Cipher Pharmaceuticals Inc. position as of Q4 2015 after selling out during the quarter.
  • Barclays sold 300 Cipher Pharmaceuticals Inc. shares in Q4 2015, an estimated $1K.
  • Barclays first reported a position in Cipher Pharmaceuticals Inc. in Q3 2015 and held it in 1 quarter.
  • Barclays's Cipher Pharmaceuticals Inc. position peaked at $1K in Q3 2015.
  • 21 funds tracked by Wall St. Rank held Cipher Pharmaceuticals Inc. as of Q4 2015.

Based on Barclays's 13F filing for Q4 2015, filed 12 Feb 2016.